Diabetes Type 2

Diabetes Type 2

A multicenter, randomized, double blind, placebo-controlled, phase 3 study to evaluate cardiovascular outcomes of TAK-875, 50 mg in addition to standard of care in subjects with Type 2 diabetes and with cardiovascular disease or multiple risk factors for cardiovascular events.

Sponsored by Takeda Global Research & Development Center

The purpose of this study is to evaluate the risk of cardiovascular events in high risk patients with Type 2 diabetes mellitus when they are treated with TAK-875 as compared with placebo. Patients who are eligible for this study must have had a heart attack within the past two years, or have peripheral vascular disease, or have had a stroke or TIA within the past two years.

Subjects will receive their usual care for their diabetes and will be randomly assigned to receive either a placebo or TAK-875 in addition. The study will last for up to 6 years and will enroll 5000 patients. More information can be found here.  

ClinicalTrials.gov Identifier: NCT01609582

Principal Investigator: Christopher Rogers, DO

Study Status: Enrolling

Study Contacts

Gail Massey, RN, BS, CCRP
(269) 341-8774


Bronson Advanced Cardiac Healthcare
601 John St., Suite 100, Center Building
Kalamazoo, MI 49007

Related Information

Icon of a hand holding a heart-shaped token.

Help Bronson support our community with a monetary donation.

Donate today